Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 26.92
+0.88 (3.38%)
Aug 29, 2025, 2:45 PM CST
Hybio Pharmaceutical Revenue
Hybio Pharmaceutical had revenue of 239.47M CNY in the quarter ending June 30, 2025, with 127.07% growth. This brings the company's revenue in the last twelve months to 883.92M, up 144.29% year-over-year. In the year 2024, Hybio Pharmaceutical had annual revenue of 590.20M with 36.82% growth.
Revenue (ttm)
883.92M
Revenue Growth
+144.29%
P/S Ratio
26.89
Revenue / Employee
854.03K
Employees
1,035
Market Cap
23.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 590.20M | 158.81M | 36.82% |
| Dec 31, 2023 | 431.38M | -272.94M | -38.75% |
| Jan 1, 2023 | 704.32M | -31.65M | -4.30% |
| Jan 1, 2022 | 735.97M | 14.25M | 1.97% |
| Dec 31, 2020 | 721.72M | 107.53M | 17.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 30.15B |
| Shenzhen Mindray Bio-Medical Electronics | 32.94B |
| WuXi AppTec | 41.90B |
| Sichuan Biokin Pharmaceutical | 441.19M |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.52B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |